Recently, Dr. Olaleye's work has been on the development of new therapeutic agents for treatment of drug resistant TB and HIV co-infection. TB is the leading cause of death in HIV patients worldwide. The apparent lethal synergy of TB with HIV has made the requirement for the development of new anti-TB and anti-HIV agents more imperative. She has identified and characterized potential drug candidates for chemotherapy of TB and HIV co-infection. Furthermore, she developed a high throughput screening assay to screen for novel inhibitors that have activity against TB and HIV.
Publications/Creative Works
Click here to search for this faculty member's publications on PubMed.
Important Disclaimer: The responsibility for the accuracy of the information contained on these pages lies with the authors and user providing such information.